Abstracts

SYMPTOM AND VIRAL REBOUND IN UNTREATED COVID-19 INFECTION

Background: Rebound of SARS-CoV-2 RNA and symptoms has been reported in people treated with nirmatrelvir/ritonavir. Since the natural course of viral and symptom trajectories during COVID-19 have not been well described, we evaluated the incidence of viral rebound and symptom relapse in untreated individuals with mild-to-moderate COVID-19. Methods: This analysis included 563 participants randomized to…

SAFETY AND EFFICACY OF INHALED INTERFERON-β1A (SNG001) IN OUTPATIENTS WITH COVID-19

Background: SARS-CoV-2 variants resistant to monoclonal antibodies, and drug-drug interactions and potential mutagenicity of direct acting antivirals, heightens the need for additional therapeutics to prevent progression to severe COVID-19. Exogenous interferon beta is a promising therapeutic option against SARS-CoV-2 given its broad-spectrum antiviral activity and data suggesting impaired endogenous IFN production in individuals with severe…

CHARACTERIZATION OF SINGLE VERSUS DUAL ACTIVE mAB AGAINST SARS-CoV-2

Background: Amubarvimab and romlusevimab are anti-SARS-CoV-2 monoclonal antibodies (mAbs) that significantly reduced the risk of hospitalizations or death in the ACTIV-2/A5401 trial. SARS-CoV-2 variants (e.g., Delta, Epsilon, Lambda) harbor mutations against romlusevimab. We evaluated viral kinetics and resistance emergence in individuals treated with mono versus dual-active mAbs. Methods: The study population included 789 non-hospitalized participants…

EFFECT OF EARLY TREATMENT WITH PEGYLATED INTERFERON LAMBDA FOR COVID-19

Background: We assessed the efficacy of a single dose of peginterferon lambda in preventing clinical events among acutely symptomatic COVID-19 outpatients. Methods: We conducted a placebo-controlled, randomized, adaptive platform trial among predominantly vaccinated SARS-CoV-2-positive adults in Brazil and Canada receiving either one subcutaneous injection of peginterferon lambda or placebo. The primary composite endpoint was medical…

METFORMIN REDUCED SARS-CoV-2 VIRAL LOAD IN A PHASE 3 RANDOMIZED CLINICAL TRIAL

Background: Metformin has in vitro activity against SARS-CoV-2. In a published phase 3, quadruple-blinded, placebo-controlled randomized trial of outpatient COVID-19 therapy, metformin resulted in a 42% reduction in ER visits/hospitalizations/deaths by day 14, 58% reduction in hospitalizations/death by day 28, and 42% reduction in Long Covid through 10 months. This analysis presents the results of…

CAB LA FOR HIV PREVENTION IN AFRICAN CISGENDER FEMALE ADOLESCENTS (HPTN 084-01)

Background: While adolescents represent a key population in need of HIV prevention worldwide, daily oral TDF/FTC pre-exposure prophylaxis (PrEP) confers adherence challenges that limit effectiveness. This single arm, open-label Phase 2b safety study (HPTN 084-01) examined the safety, tolerability and acceptability of long-acting injectable cabotegravir (CAB-LA) among adolescent cisgender females in South Africa, Uganda and…

SAFETY AND PK/PD OF A TENOFOVIR ALAFENAMIDE/ELVITEGRAVIR INSERT ADMINISTERED RECTALLY

Background: On-demand topical products for rectal use are desired by the community and could be an important tool for HIV prevention. A tenofovir alafenamide/elvitegravir (TAF/EVG) fast-dissolve insert has demonstrated protective efficacy in a NHP SHIV rectal challenge model. We evaluated the safety and pharmacokinetics (PK) of the TAF/EVG insert administered rectally at two dose levels.…

8+ YEARS POOLED ANALYSIS: ADHERENCE AND HIV INCIDENCE IN 6000 WOMEN ON F/TDF FOR PrEP

Background: Daily emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP) substantially reduces HIV acquisition. This multinational pooled analysis summarizes data from >6000 women followed since F/TDF for PrEP approval in 2012 to better understand adherence and HIV prevention. Methods: We obtained demographic, adherence, and HIV-1 status for cisgender women on F/TDF for PrEP at…

ENSITRELVIR FOR MILD-TO-MODERATE COVID-19: PHASE 3 PART OF PHASE 2/3 STUDY

Background: Ensitrelvir is a SARS-CoV-2 3CL protease inhibitor approved in Japan under emergency regulatory approval system as an oral treatment for COVID-19. Here we report the key analysis results of 125 mg group of phase3 part (SCORPIO-SR). Methods: This study was a multicenter, randomized, double-blind, placebo-controlled study. Regardless of SARS-CoV-2 vaccination status and presence of…

ULTRA LONG-ACTING REFILLABLE ISLATRAVIR IMPLANT FULLY PROTECTS NHP AGAINST SHIV

Background: When taken as prescribed, antiretroviral (ARV) drugs are effective as pre-exposure prophylaxis (PrEP) against human immunodeficiency virus (HIV) transmission. However, consistent adherence to daily dosing regimen is challenged by issues such as pill fatigue, forgetfulness, stigma or lifestyle discordance. To this end, long-acting approaches with infrequent dosing intervals aim at improving therapeutic adherence and…